Index

	Plaquex^® History The Plaquex^® Formula has been in use for the past 55 years in about one-fourth of the world's countries¹. It was originally developed to dissolve fatty embolus during and after trauma surgery. It was also used to treat liver disease². In the 1990's the use shifted to treating plaque deposits. The treatment was mostly done in combination with EDTA chelation infusions. Since then results have been so dramatic, that it has become a treatment in its own right.

	Not only is the Plaquex^® Formula used to remove fatty and hardened plaque from blood vessels, it is also applied for general anti aging purposes¹. By observing their patients, many doctors discovered that the patients started looking younger and healthier after the have had about 20 treatments.

	In 2006 Plaquex^®Oral Gel Capsules were added to the treatment regimen. They improve blood lipids and liver function and thereby aid in the prevention of plaque deposits in between IV treatment sessions.

	Chosen for their uncompromising quality and superior performance, AnazaoHealth^® looks forward to sharing more than a decade of experience with you. Their staff of pharmacists, technicians and account managers are available to answer your questions about preparations, ordering and delivery.

	AnazaoHealth^® is fully licensed to provide prescriptions in all 50 states and the District of Columbia. We encourage you to learn more about them by visiting their website at www.anazaohealth.com.


	This website will provide you with help to find basic information, detailed studies, important contact information and to answer frequently asked questions regarding the original Plaquex^® product.


	References
	¹ Elevation of HDL, LDL, and liver enzymes in the beginning which normalize with continuing treatment Leuschner, F. A. Leuschner. Research report no. 0050/84 of December 27, 1983 Maeda, A. et al. Gendai no Shinryo 22 (1980) 189-192 and 1461-1465 Fasoli, A. Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262 Suo, T. et al. Kiso to Rinsho 15 (1981) 3046-3051 Belousova, S.S. et al. Kardiologiya 25 (1985) 112-115 Izumi, H. et al. 11^th Proceed Jap. Atheroscl. Socl, Tokyo 1979 Nakamura, H. et al. Jap J. New. Rem. Clin. 22 (1973) 1565-1575 Spigai, C. Med. Heute 19 (1970) 197-198 Thurnherr A. Therapiewoche 7 (1956) 116 Friehe, H., R. Fontaine Report no. 840160 of December 16, 1978 Arsenio, L. et al. Clin. Ter. 114 (1985) 117-127 Tomasevic, M. Unpublished report no. 842746 Takahashi, S. Shinryo to Shinyaku 17 (1980) 3051-3064 Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38 ² Angina Pectoris Serkova, V.K. Klin. Med. (Moscow) 64 (1986) 91-95 Spesivtseva, V. G. et al., Lipostabil Symposium Moscow, Nov. 1984 Kalmykova, V.I., E. B. Zakharova, Sov. Med. 4 (1989) 5-9 Peripheral Vascular Klemm, J. In: Phosphatidylcholine. H. Peeters (ed.) Springer: Berlin 1976, 237-243 Luczac, Z., R. Leutschaft. Unpublished report no. 842762 Pristautz, H. Munch. Med. Wschr. 117 (1975) 583-586 Hevelke, G. et al. Med. Welt 30 (1980) 593-602 Liver disease Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4^th Int. Sympos. Atheroscl., Tokyo 1976 and: Diab. Obes. Hyperlipoprot., Cupaldi, V. et al. (eds.), Academic Press: New York 1987 Salvioli, G. Scand J. Gastroenterology 12 (1977) 841-847 Salvioli, G. et al. Gut 19 (1978) 844-850 Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99 Cell Membranes Ehrly, A.M. Report no. 842276 of March 17, 1975 – and R. Blendin in: Phosphatidylcholine, H. Peeters (ed.) Springer: Berlin 1976, 228-236 Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38 ³Nei’mark Al, Zhukov, VN et al. Use of isradipine and EPL for protection of the kidney during extracorporal lithotripsy Urologiia I Nefrologiia. (6):19-21, 1998 Nov-Dec ⁴Kuntz, E. The “essential” phospholipids in hepatology – 50 years of experimental and clinical experiences Z Gastroenterol (Suppl 2) 1991: 29:7-13